NYSEAMERICAN:PFNX Pfenex (PFNX) Stock Price, News & Analysis $12.75 0.00 (0.00%) As of 10/1/2020 Add Compare Share Share Stock Analysis Stock Analysis About Pfenex Stock (NYSEAMERICAN:PFNX) Get Pfenex alerts:Sign Up Key Stats Today's Range$12.75▼$12.7550-Day Range$12.75▼$12.7552-Week Range$5.26▼$14.00VolumeN/AAverage Volume503,865 shsMarket Capitalization$437.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pfenex was a biotechnology company that developed recombinant proteins and biosimilar medicines using its Pfenex Expression Technology platform. Its work focused on producing complex proteins for pharmaceutical applications. The company advanced PF708, a teriparatide injection later marketed as Bonsity, and collaborated with Pfizer on PF-06439535, a bevacizumab biosimilar marketed as Zirabev. These products were developed for markets including the United States and other countries through commercial partnerships. Based in San Diego, California, Pfenex became part of Ligand Pharmaceuticals after Ligand completed its acquisition of the company in 2020.AI Generated. May Contain Errors. Read More Receive PFNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFNX Stock News HeadlinesNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLigand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking AlphaSeptember 25, 2022 | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 18 at 1:00 AM | Weiss Ratings (Ad)Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business WireAugust 15, 2022 | businesswire.comLigand Reports Second Quarter 2022 Financial Results - Business WireAugust 9, 2022 | businesswire.com2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - StockhouseAugust 8, 2022 | stockhouse.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo FinanceMay 17, 2022 | finance.yahoo.comLigand Reports First Quarter 2022 Financial Results - StreetInsider.comMay 5, 2022 | streetinsider.comSee More Headlines PFNX Stock Analysis - Frequently Asked Questions How have PFNX shares performed this year? Pfenex's stock was trading at $12.75 at the beginning of 2026. Since then, PFNX shares have increased by 0.0% and is now trading at $12.75. How were Pfenex's earnings last quarter? Pfenex Inc. (NYSEAMERICAN:PFNX) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $680 thousand for the quarter, compared to analysts' expectations of $3.75 million. What other stocks do shareholders of Pfenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pfenex investors own include Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Bank of America (BAC), Anheuser-Busch InBev SA/NV (BUD), Salesforce (CRM), Applied Materials (AMAT) and Advanced Micro Devices (AMD). Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:PFNX Previous SymbolNYSEMKT:PFNX CIKN/A Webwww.pfenex.com Phone+1-858-3524400FaxN/AEmployees71Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,297,000Free FloatN/AMarket Cap$437.29 million OptionableNot Optionable BetaN/A Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSEAMERICAN:PFNX) was last updated on 10/1/2020 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEarly bird access on this Black Friday dealMarkham Trading's Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 for access...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfenex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfenex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.